Literature DB >> 6432921

Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement.

G B Pier, P Ames.   

Abstract

The mechanism of killing of 12 serum-sensitive strains of mucoid Pseudomonas aeruginosa isolated from patients with cystic fibrosis was investigated. A quantitative assay indicated that more than 90% of cells were killed in 50% normal human serum (NHS). All strains failed to grow in NHS concentrations of greater than 10%. Killing was unaffected by adsorption of NHS with the mucoid bacteria or chelation with MgCl2-ethyleneglycol bis(beta-aminoethyl ether)N,N1-tetraacetate (MgCl2-EGTA) but was abolished in serum heated to 50 C for 20 min. Incubation of NHS with mucoid P. aeruginosa reduced the hemolytic capability of MgCl2-EGTA-chelated NHS against rabbit red blood cells by 56%-99%. Killing of the serum-sensitive mucoid strains was also seen in hypogammaglobulinemic serum. These data suggest that killing of such strains by NHS can occur via antibody-independent activation of the alternative pathway of complement. The importance of this finding lies in the implication that complement levels in the lungs of patients with cystic fibrosis who are colonized by these organisms are inadequate to deal with this chronic, progressive infection.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432921     DOI: 10.1093/infdis/150.2.223

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Nitrite reductase from Pseudomonas aeruginosa induces inflammatory cytokines in cultured respiratory cells.

Authors:  K Oishi; B Sar; A Wada; Y Hidaka; S Matsumoto; H Amano; F Sonoda; S Kobayashi; T Hirayama; T Nagatake; K Matsushima
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

2.  Nitrite reductase from Pseudomonas aeruginosa released by antimicrobial agents and complement induces interleukin-8 production in bronchial epithelial cells.

Authors:  B Sar; K Oishi; A Wada; T Hirayama; K Matsushima; T Nagatake
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Kinetics of serum, tear, and corneal antibody responses in resistant and susceptible mice intracorneally infected with Pseudomonas aeruginosa.

Authors:  M J Preston; K A Kernacki; J M Berk; L D Hazlett; R S Berk
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model.

Authors:  Akinobu Kamei; Andrew Y Koh; Mihaela Gadjeva; Gregory P Priebe; Stephen Lory; Gerald B Pier
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

Review 5.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

6.  Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.

Authors:  P Ames; D DesJardins; G B Pier
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Cloning and surface expression of Pseudomonas aeruginosa O antigen in Escherichia coli.

Authors:  J B Goldberg; K Hatano; G S Meluleni; G B Pier
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

Review 8.  Pseudomonas aeruginosa lipopolysaccharide: a major virulence factor, initiator of inflammation and target for effective immunity.

Authors:  Gerald B Pier
Journal:  Int J Med Microbiol       Date:  2007-04-27       Impact factor: 3.473

Review 9.  Pseudomonas aeruginosa virulence and therapy: evolving translational strategies.

Authors:  Jeffrey L Veesenmeyer; Alan R Hauser; Thiago Lisboa; Jordi Rello
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

10.  In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

Authors:  G B Pier; D Thomas; G Small; A Siadak; H Zweerink
Journal:  Infect Immun       Date:  1989-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.